Compare Merck & Co., Inc. (MRK) vs Seagate Technology Holdings PLC (STX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Seagate Technology Holdings PLC — how do they compare? Merck & Co., Inc. trades at $146.32 (market cap $351.28B), while Seagate Technology Holdings PLC trades at $781.69 (market cap $176.19B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Seagate Technology Holdings PLC for 41 Days on average.
| MRK | STX | |
|---|---|---|
Market Cap | $351.28B | $176.19B |
Volume | 7,969,665 | 5,061,875 |
Sector | Health | Technology |
52-Week High | $156.43 | $1.09K |
52-Week Low | $82.49 | $211.63 |
Typical Hold Time | 98 Days | 41 Days |
Enterprise Value | $398.04B | $178.34B |
Dividend Yield | 2.39% | 0.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Seagate Technology (STX) trades at $780.39, down 3.34% amid concerns about increased competition from Toshiba's planned HDD production expansion. The stock shows strong fundamental performance with Q2 2026 EPS beating expectations at $5.71 versus $5.10, and maintains robust profitability with 26.11% net margin and 371.53% ROE. Technical indicators signal bearish momentum with price below key pivot points, though RSI suggests potential oversold conditions at 24.89.
Despite near-term competitive pressures, Seagate's dominant position in AI storage and strong earnings trajectory support long-term growth. The consensus price target of $1,130 represents 45% upside potential, but investors face risks from pricing pressure and market share erosion as Toshiba expands capacity in 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Seagate Technology Holdings PLC
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →
